Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 13;16(1):308.
doi: 10.1186/s13023-021-01923-0.

Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group

William A Gahl  1 , Durhane Wong-Rieger  2 , Virginie Hivert  3 , Rachel Yang  4 , Galliano Zanello  5 , Stephen Groft  6
Affiliations

Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group

William A Gahl et al. Orphanet J Rare Dis. .

Abstract

Background: Treatments are often unavailable for rare disease patients, especially in low-and-middle-income countries. Reasons for this include lack of financial support for therapies and onerous regulatory requirements for approval of drugs. Other barriers include lack of reimbursement, administrative infrastructure, and knowledge about diagnosis and drug treatment options. The International Rare Diseases Research Consortium set up the Rare Disease Treatment Access Working Group with the first objective to develop an essential list of medicinal products for rare diseases.

Results: The Working Group extracted 204 drugs for rare diseases in the FDA, EMA databases and/or China's NMPA databases with approval and/or marketing authorization. The drugs were organized in seven disease categories: metabolic, neurologic, hematologic, anti-inflammatory, endocrine, pulmonary, and immunologic, plus a miscellaneous category.

Conclusions: The proposed list of essential medicinal products for rare diseases is intended to initiate discussion and collaboration among patient advocacy groups, health care providers, industry and government agencies to enhance access to appropriate medicines for all rare disease patients throughout the world.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Stevens H, Huys I. Innovative approaches to increase access to medicines in developing countries. Front Med. 2017;4:218. doi: 10.3389/fmed.2017.00218. - DOI - PMC - PubMed
    1. Detiček A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. 2018;21:553–560. doi: 10.1016/j.jval.2018.01.007. - DOI - PubMed
    1. Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, et al. Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis. Value Health. 2020;23:1580–1591. doi: 10.1016/j.jval.2020.06.020. - DOI - PubMed
    1. Kishore SP, Kolappa K, Jarvis JD, Park PH, Belt R, Balasubramaniam T, et al. Overcoming obstacles to enable access to medicines for noncommunicable diseases in poor countries. Health Aff. 2015;34:1569–1577. doi: 10.1377/hlthaff.2015.0375. - DOI - PubMed
    1. Search Orphan Drug Designations and Approvals [Internet]. U.S. FOOD & DRUG Administration. [cited 2021 Jan 29]. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/.

Publication types